Better Buy: Moderna vs. BioNTech

Some investors enjoy taking a "basket" approach to investing in an emerging technology. Spreading their dollars across a few companies ensures their returns are tied to the overall technological trend, instead of one business or management team. Other investors, wanting to maximize returns (and willing to take more risk), will dig deeper to try and pick a winner in the industry. 

For those looking to choose between shares in makers of coronavirus vaccines, two companies that are leveraging an emerging gene-based medicine technology present an opportunity to profit. The upside isn't just in the coronavirus vaccine, it's also in what it means for treating diseases in the future. Both Moderna (NASDAQ: MRNA) and BioNTech SE (NASDAQ: BNTX) are using messenger ribonucleic acid (mRNA or messenger RNA) -- genetic instructions that tell cells to make proteins that fight, or even prevent, diseases -- to create a vaccine for the novel coronavirus, and investors looking to choose between them should focus on a few differentiating factors.

After yesterday's news demonstrating the efficacy of the Pfizer/BioNTech vaccine candidate, investors may think the battle here is over. However, the news, while exciting, is just the first step down the path to approval, distribution, and profits for a vaccine. 

Continue reading

Source Fool.com